Orlando Clinical Research Center
Nephrology
Dr. Thomas C. Marbury, MD
|
|
Give Review
Thomas Marbury is an expert in the field of Nephrology. He attended University of Texas Medical School. Dr. Thomas C. Marbury is a published physician. He published 101 publications, including: 'Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal diseas...'
Publications
- GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study.
- Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib.
- Pharmacokinetic Properties of Fostamatinib in Patients With Renal or Hepatic Impairment: Results From 2 Phase I Clinical Studies.
- Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment.
- Effect of Hepatic or Renal Impairment on the Pharmacokinetics of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor.
- Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment.
- Pharmacokinetics, pharmacodynamics, and safety of peginterferon beta-1a in subjects with normal or impaired renal function.
- Pharmacokinetics of renally excreted drug dexpramipexole in subjects with impaired renal function.
- The Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Ospemifene, a Tissue-Selective Estrogen Agonist/Antagonist.
- The Effect of Mild to Moderate Renal Impairment on the Pharmacokinetics of the Nucleoside Analog Hepatitis C Virus Polymerase Inhibitor Mericitabine.
- Single-dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment.
- Multiple ascending dose study of BMS-790052, an NS5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1.
- The Pharmacokinetics of PF-734200, a DPP-IV Inhibitor, in Subjects With Renal Insufficiency.
- Pharmacokinetics of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, in patients with moderate hepatic impairment.
- Pharmacokinetics of Oral Dexamethasone and Midazolam When Administered With Single-Dose Intravenous 150 mg Fosaprepitant in Healthy Adult Subjects.
- Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist.
- Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.
- Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function.
- Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects.
- Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.
- Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
- Pharmacokinetics of maribavir, a novel oral anticytomegalovirus agent, in subjects with varying degrees of renal impairment.
- Pharmacokinetics of telbivudine in subjects with various degrees of hepatic impairment.
- Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction.
- Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily.
- Pharmacokinetics of etoricoxib in patients with renal impairment.
- Pharmacokinetics and safety of a single oral dose of once-daily alfuzosin, 10 mg, in male subjects with mild to severe renal impairment.
- Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction.
- A randomized, double-blind, multicenter comparison of gatifloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection and pyelonephritis.
- Clearance and recovery calculations in hemodialysis: application to plasma, red blood cells, and dialysate measurements for cyclophosphamide.
- Hemodialysis of acetaminophen in uremic patients.
- Hemodialysis clearance and total body elimination of carbamazepine during chronic hemodialysis.
- Hemodialysis of mefenamic acid in uremic patients.
- Clearance calculations in hemodialysis: application to blood, plasma, and dialysate measurements for ethambutol.
- Hemodialysis clearance of ethosuximide in patients with chronic renal disease.
- Hemodialysis for acetaminophen detoxification.
- Pharmacokinetics of dyphylline elimination by uremic patients.
- Combined antidotal and hemodialysis treatments for nitroprusside-induced cyanide toxicity.
- Pharmacokinetics of primidone elimination by uremic patients.
- Comparative pharmacokinetics of theophylline in peritoneal dialysis and hemodialysis.
- Protein binding of valproic acid in uremic patients.
- Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations.
- The effect of indomethacin on plasma renin activity response to ultrafiltration in patients undergoing hemodialysis.
- Hemolytic uremic syndrome in two postmenopausal women taking a conjugated estrogen preparation.
- Quadriceps tendon ruptures in uremia.
- Intravascular clotting preceding crescent formation in a patient with Wegner''s granulomatosis and rapidly progressive glomerulonephritis.
- Hemodialysis of theophylline in uremic patients.
- Severe diarrhea secondary to propranolol.
- Clinical utility of long-term enalapril/diltiazem ER in stage 3-4 essential hypertension. Long-term Use of Enalapril/Diltiazem ER in Stage 3-4 Hypertension Group.
- Evaluation of enalapril combined with diltiazem ER in patients with stage 3-4 essential hypertension.
- Comparison of the fixed combination of enalapril/diltiazem ER and their monotherapies in stage 1 to 3 essential hypertension.
- Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators.
- Anaritide in acute tubular necrosis. Auriculin Anaritide Acute Renal Failure Study Group.
- A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients.
- Flexible prandial glucose regulation with repaglinide in patients with type 2 diabetes.
- Pharmacokinetics of repaglinide in subjects with renal impairment.
- Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.
- Safety and efficacy of short-duration oral terbinafine for the treatment of tinea corporis or tinea cruris in subjects with HIV infection or diabetes.
- Pharmacokinetics, pharmacodynamics, and dose-response relationship of repaglinide in type 2 diabetes.
- Atrial natriuretic factor in oliguric acute renal failure. Anaritide Acute Renal Failure Study Group.
- Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension.
- Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval.
- A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
- Safety and pharmacokinetics of subcutaneously administered rilonacept in patients with well-controlled end-stage renal disease (ESRD).
- Single-Dose pharmacokinetics of sustained-release fampridine (Fampridine-SR) in healthy volunteers and adults with renal impairment.
- Examination of the effect of increasing doses of etoricoxib on oral methotrexate pharmacokinetics in patients with rheumatoid arthritis.
- Zelrix: a novel transdermal formulation of sumatriptan.
- Renal insufficiency has no effect on the pharmacokinetics of vicriviroc in a ritonavir-containing regimen.
- Clinical pharmacokinetics of tonapofylline: evaluation of dose proportionality, oral bioavailability, and gender and food effects in healthy human subjects.
- Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics.
- Comparison pharmacokinetics of two concentrations (0.7% and 1.0%) of Nasulin, an ultra-rapid-acting intranasal insulin formulation.
- Enhanced absorption of Nasulin™, an ultrarapid-acting intranasal insulin formulation, using single nostril administration in normal subjects.
- Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receivi...
- Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment.
- Asenapine pharmacokinetics in hepatic and renal impairment.
- Multiple-dose pharmacokinetics of peginterferon alfa-2b in patients with renal insufficiency.
- Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor.
- Garenoxacin pharmacokinetics in subjects with renal impairment.
- Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects.
- Effect of impaired renal function and haemodialysis on the pharmacokinetics of aprepitant.
- The effect of ketoconazole on the pharmacokinetics of a selective alpha 1A-adrenoceptor antagonist.
- Pharmacokinetics and safety of the ketolide telithromycin in patients with renal impairment.
- Effects of renal insufficiency and hemodialysis on the pharmacokinetics of rofecoxib.
- Oral bioavailability of desloratadine is unaffected by food.
- Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials.
- Long-term safety and antihypertensive efficacy of irbesartan: pooled results of five open-label studies.
- Pharmacokinetics of sparfloxacin in patients with renal impairment.
- Repaglinide versus glyburide: a one-year comparison trial.
- Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal diseas...
- An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators.
- Lower dose diuretic therapy in the treatment of patients with mild to moderate hypertension.
- Comparative efficacy and tolerability of two long-acting calcium antagonists, mibefradil and amlodipine, in essential hypertension. Mibefradil Hypertension Study Group.
- Advanced digoxin toxicity in renal failure: treatment with charcoal hemoperfusion.
- Effectiveness of indapamide versus enalapril as second-step therapy of systemic hypertension.
- Chronic renal vein thrombosis.
- A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pres...
- Influence of renal function on the pharmacokinetics of cerivastatin in normocholesterolemic adults.
- Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim, compared to AndroGel.
- Cardiovascular safety of sublingual apomorphine in patients on stable doses of oral antihypertensive agents and nitrates.
- A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults.
Schools
University Of Texas Medical School At Houston
Brackenridge Hospital
University Fla
Doctors Specialties
- Nephrology
Accepted Insurances
Education
-
University of Florida -
University of Texas Medical School
Hospital
-
Orlando Regional Medical Center
Helpful Reviews
Similar Doctors
|
|
Dr. Uday K. Ranjit, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alfred Rodriguez, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Paul T. Dreyer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Romita Mukerjee, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Robert M. Sullivan, MD |
|
|
Dr. Vincent Alfieri, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Abdo R. Asmar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jorge A. Kusnir, MD
This Doctor is OpenDoctor Recommended.
|